Chart-Typ:
Zeitraum:
| Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA (vonoprazan) Tablets through May 3, 2032 | FLORHAM PARK, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) today announced that the U.S. Food and Drug Administration (FDA) has approved Phathom's Citizen Petition... ► Artikel lesen |
| Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen |
| Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update | VOQUEZNA launch momentum continues with over 390,000 prescriptions filled to date, written by more than 23,600 healthcare providersNet revenues of $28.5 million reported for Q1Filled VOQUEZNA prescriptions... ► Artikel lesen |
| Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen |
| Avidity Biosciences, Inc.: Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights | On track to deliver key regulatory updates for del-brax and topline data from dose escalation cohorts in the FORTITUDE trial in the second quarter
Positive topline... ► Artikel lesen |
| Avidity Biosciences, Inc.: Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy | Del-brax FORTITUDE biomarker cohort designed for potential accelerated approval; plan to share regulatory update in Q2 2025
Regulatory alignment on global Phase... ► Artikel lesen |
| Biotech Report: Qiagen und Biontech wenig bewegt, US-Sektor fest | (shareribs.com) Frankfurt / New York 06.06.2025 - Biotech-Werte zeigten sich im deutschen Handel durchwachsen. Biontech und Qiagen korrigierten leicht. An der Wall Street legte der Sektor hingegen deutlich... ► Artikel lesen |
| Tracer Biotechnologies Announces Strategic Partnership with QIAGEN to Advance Blood-Based MRD Testing for Solid Tumors | Tracer Biotechnologies, a leader in blood-based molecular diagnostics for cancer, is pleased to announce a strategic partnership with QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) to co-develop... ► Artikel lesen |
| Biotech Report: Evotec und Qiagen klettern, Biontech rutschen ab | (shareribs.com) Frankfurt / New York 04.06.2025 - Biotechnologiewerte bewegen sich im deutschen Handel überwiegend nach oben. Auch an der Wall Street legt der Sektor weiter zu. Der DAX steigt um 0,7... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ULISSE BIOMED SPA finden Sie auf Wallstreet Online.